Test

Aluminum (AAS)

Other Test Request Name

• Al

Test Composition

Not applicable

Intended Use

Aluminum has toxic effects on the nerveous system and in bone tissue. Patients on dialysis, antacid therapy or parenteral alimanation should be monitored.

Methodology

Atomic Absorption Spectrophotometry / ICP-MS

Laboratory Section

Special Test

 Special Instructions/Patient Preparations

No patient preparation necessary.

Collection/Sample Container

Sodium Heparin or Lithium Heparin (Green Top)

 

 

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

3 mL Plasma

Alternative Specimen and Volume Requirement

Not Applicable

 

Specimen Stability

•   Room Temperature (15-25°C)

1 Hour

•   Refrigerated Temperature (2-8°C)

14 Days

 

•   Freezer Temperature (-20°C)

Not applicable

Transport Temperature

Transport specimen at 2 – 8 °C (with cold packs)

Rejection Criteria

 

• Clotted specimens
• Quantity Not sufficient
• Improperly labeled specimen
• Overfilled or underfilled tube
• Specimen stored and transported outside the required temperature

Running Day

Batch Running

Cut Off Time

Friday 4:00 PM

TAT/Releasing of Results

3 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Reference Interval/Result Interpretation

Available upon request

Limitations/Interferences

None specified.

Frequently Asked Questions (FAQs)

Not applicable

Related Words/Test

Trace / Heavy metals

 

 

 

 

 

 

Test

Aluminum (Dialysate/H2O)

Other Test Request Name

• Al

Test Composition

Not applicable

Intended Use

• It is used as antacid and cytoprotectant. In terminal renal failure, it is used to complex phosphate in the intestine, thereby inhibiting its absorption and reducing its concentration in the blood, which if abnormally high, can lead to hyperparathyroidism, a common complication of renal insufficiency.

Methodology

Atomic Absorption Spectrophotometry

Laboratory Section

Special Test

Special Instructions/Patient Preparations

No patient preparation necessary.

Collection/Sample Container

Sterile Container

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

20 ml Water

Alternative Specimen and Volume Requirement

Not Applicable

Specimen Stability

•   Room Temperature (15-25°C)

14 Days

•   Refrigerated Temperature (2-8°C)

Not applicable

•   Freezer Temperature (-20°C)

Not applicable

Transport Temperature

Transport specimen at 2 – 8 °C (with cold packs)

Rejection Criteria

• Quantity Not sufficient
• Improperly labeled specimen
• Specimen stored and transported outside the required temperature

Running Day

Batch Running

Cut Off Time

Friday 4:00 PM

TAT/Releasing of Results

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Reference Interval/Result Interpretation

Available upon request

Limitations/Interferences

None specified.

Frequently Asked Questions (FAQs)

Not applicable

Related Words/Test

Dementia, Osteodystrophy, Anemia, Renal Dialysis

Test

Ambulatory Blood Pressure Monitor Test

Other Test Request Name

24 Hour Ambulatory Blood Pressure Monitoring

Test Composition

Intended Use

A 24-hour ambulatory blood pressure monitoring is a way of measuring and managing high blood pressure (hypertension).It is just the same as a normal blood pressure check: a digital machine takes the blood pressure readings and records it over a 24-hour period as the patient moves around, living his/her normal daily life and even when asleep.  It is used to:

  • Provide accurate information on blood pressure variability, overnight dipping and morning surge for reliable hypertension management and control.
  • Detect abnormal fluctuations in BP that might go unnoticed when BP is only measured in the doctor’s office. It is a very useful way to detect white coat hypertension, masked hypertension, and sustained hypertension.
  • Determine how well some antihypertensive drugs can control high BP. This includes those patients who have difficulty controlling their BP even with medication; BP changes due to other drugs or changes in prescription medications that may impact BP.
  • Help predict the likelihood of cardiovascular (blood vessels in the heart) and cerebrovascular (blood vessels in the brain) disease linked to hypertension and organ damage.

It can also be suitable in other situations, such as Elderly patients and Type 1 Diabetes who are at risk of having hypertension; Pregnant women with hypertension (pre-eclamptic); patients experiencing fainting episodes or hypotension (low BP); nocturnal hypertension (whether or not blood pressure falls at night compared to daytime values).

Methodology

Laboratory Section

IMAGING DEPARTMENT

Special Instructions/Patient Preparations

BRANCH & SCHEDULE

All HPD & HPD Plus branches - By appointment

PREPARATION

  • No fasting requirement.
  • Patient must take a bath or shower before coming to the appointment as he/shewill not be able to do so while wearing the device.
  • Wearing a thin shirt under the cuff is recommended to prevent problems caused by long-time wear of the cuff (sweat, itching, soreness, etc.)

WHILE WEARING THE DEVICE

  • Before the machine is about to take a reading, sit down, if possible keep the cuff at the same level as the heart; keep the arm steady and do not talk or cross legs during the recording.
  • Avoid blocking the air flow in the tube of the cuff and twisting the tube. Avoid excess movement and bending or folding of the arm during blood pressure measurements. They should hold their arm loose, slightly away from their chest.
  • Use the buttons, if necessary.
    • Press the start button to initiate extra blood pressure measurement.
    • Press the medication button to mark events, i.e. taking medication etc.
    • Press the day/night button to mark the time rising from and going to bed.
  • Should the blood pressure measurements cause blood shots, torpidity or pain in the hand, the cuff should be removed from the arm immediately and disconnected from the recorder. Such occurrence should be reported to the physician latest after the monitoring session.
  • Don’t remove the recorder even at night. By loosening the straps, patients can avoid problems when turning in their sleep. The recorder does not disturb most patients at night.
  • Should the batteries run down during a monitoring session, they can simply be replaced. Monitoring will continue and data will not be lost.
  • Keep a diary to track down activities or events including the name and dosage of the medication taken, and symptoms, observations, or complaints (e.g. pain, dizziness, etc.) experienced during the monitoring period.
  • Because the test is being carried out to find out the normal daily blood pressure is, it is important to carry on with patient's normal routine and do all the things he/she would normally do. However, it is not recommended to drive or go to gym for work out. A gentle or brisk walking is fine. Swimming and having a bath or shower are also not allowed.
  • Never measure anybody else’s blood pressure with the recorder during an ambulatory blood pressure monitoring session.

AFTER THE MONITORING PERIOD

  • Return to the clinic to submit the Patient Diary and so the technician can remove the ambulatory BP monitor device.

Collection/Sample Container

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

Alternative Specimen and Volume Requirement

Specimen Stability

•   Room Temperature (15-25°C)

•   Refrigerated Temperature (2-8°C)

•   Freezer Temperature (-20°C)

Transport Temperature

Rejection Criteria

Running Day

Cut Off Time

TAT/Releasing of Results

2 working days after the device is surrendered

NOTE: The patient’s doctor will read the activity journal and analyze the results of the monitor.

Reference Interval/Result Interpretation

Not Applicable

Limitations/Interferences

Frequently Asked Questions (FAQs)

How are 24 Hour Ambulatory Blood Pressure readings obtained?

  • BP readings are taken continually over a 24-hour period. You will wear a device that is about the same size as a portable radio. The device is attached to a belt or strap worn on the body.
  • A BP cuff that is attached to the device is worn around your non-dominant upper arm. While a reading is being taken, the cuff will inflate and squeeze your arm firmly. While the cuff is inflating and deflating, it is best to try to avoid moving your arm, as this may interfere with the reading. If the monitor has trouble getting a reading, it may re-inflate in a minute or so to try a second time. You may be told to keep a diary to record your daily readings. This can help show how changes in your BP relate to periods of activity or rest.
  • At the end of the 24 hours, you can remove the device and BP cuff and return it back. 

What happens if the patient is not able to return the Ambulatory BP recorder on time?

  • Patient will be asked to sign a consent form stating the date and time of return. In case patient will not be able to return it on time, patient needs to pay an additional P250.00 per hour since there are scheduled patient for the usage of the equipment. 

What happens if patient accidentally wets the equipment? 

  • Patients are strictly advised to avoid activities that will lead to the monitor in getting wet. Thus, patient must be informed to take a bath or shower before coming for the appointment date. In line with this, patient will be asked to sign a consent form stating that you will be responsible for the safe return of the ABPM unit and that are liable for any damages or loss incurred which includes the costs for repair or replacement of the device and its accessories.

Related Words/Test

Not Applicable

 

Test

Amikacin Trough Level -Temporarily Unavailable (currently not accepting samples)

Other Test Request Name

  • Aminoglycosides
  • Gentamicin
  • Tobramycin

Test Composition

Not applicable

Intended Use

Gentamicin, tobramycin and amikacin are aminoglycosides, a group of antimicrobials (antibiotics) that are used to treat serious bacterial infections. The level of the prescribed aminoglycoside in the blood is measured in order to adjust doses as necessary and ensure effective treatment while avoiding toxic side effects.

Methodology

ParticleTurbidimetric Inhibition Immunoassay

Laboratory Section

Special Test

Special Instructions/Patient Preparations

Collect as a trough just prior to the next dose.

• Note the following info:
- Dosage
- Date and Time of last dose intake
- Date and Time of extraction

Collection/Sample Container

Red tube (DO NOT USE GOLD TUBE or any other type of tube with gel separator)

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

3 mL Serum

Alternative Specimen and Volume Requirement

 

Not Applicable

Specimen Stability

•   Room Temperature (15-25°C)

 

    24 Hours

•   Refrigerated Temperature (2-8°C)

7 Days

 

 

•   Freezer Temperature (-20°C)

Not Applicable

Transport Temperature

Transport specimen at 2 – 8 °C (with cold packs)

Rejection Criteria

  • Hemolyzed specimen
  • Quantity Not sufficient
  • Markedly lipemic sample
  • Improperly labeled specimen
  • Specimen stored and transported outside the required temperature
  • Wrong container used

Running Day

Monday to Friday

Cut Off Time

Monday to Friday, 7:00 AM

TAT/Releasing of Results

3 days after cut-off (excluding Saturdays, Sundays and Holidays)

Reference Interval/Result Interpretation

Available upon request

Limitations/Interferences

None specified.

Frequently Asked Questions (FAQs)

 

Q: Why get tested?

A:To monitor the level of an aminoglycoside antibiotic such as gentamicin, tobramycin, or amikacin in the blood to ensure adequate dosing and help avoid toxic side effects

Q: When to get tested?

A:At regular intervals during treatment with an aminoglycoside

Q: When is it oredered?

A:Blood levels of gentamicin, tobramycin or amikacin may be monitored under a variety of conditions. For example, a person's age, kidney function, overall health, and presence of underlying conditions or symptoms of toxicity may be considered in the decision to perform the testing. The length of treatment and type of protocol used for dosing can also be factors.

Monitoring of aminiglycosides may be recommended when a person will be receiving the drug for more than 3 days. For interval dosing, testing is usually ordered after 2 to 4 doses of the aminoglycoside have been given and when the drug is expected to have reached a relatively stable level in the blood (steady state). Drug levels then may be measured again every few days or once a week and with any change in the amount or timing of the dose or with change in kidney function.

With individuals receiving extended interval dosing, no steady state of the drug will be achieved. Typically, a timed random sample is drawn 6 to 14 hours after the dose for testing.

Tests that evaluate kidney function, such as a bcreatinine test, are often performed at regular intervals during treatment with aminoglycosides. More frequent aminoglycoside monitoring may be performed for people with impaired kidney function (renal insufficiency) and for people who have an increased risk of toxic side effects, such as those taking other drugs known to adversely affect hearing and the kidneys (ototoxic or nephrotoxic).

Q: Can I have my level tested at home?

A:Although a person may receive intravenous aminoglycoside therapy at home, usually administered by a home health professional, blood levels cannot be monitored at home. The test requires specialized equipment and must be performed in a laboratory. The home health professional may draw a blood sample prior to administering the next dose of drug. This sample will be sent to a laboratory for analysis.

Related Words/Test

Therapeutic Drug Monitoring, Blood Urea Nitrogen (BUN), Creatinine, Creatinine Clearance, Vancomycin

 

 

 

 

 

 

 

Test

Amino Acid Analysis

Other Test Request Name

Not applicable

Test Composition

1-Methylhistidine, 2-Amino butyric Acid, 2-Aminoadipic Acid, 3-Methylhistidine, Alanine, Arginine, Asparagine, Aspartic Acid, Beta-Alanine, Citrulline, Cystine, Cystathionine, Ethanolamine, Glutamic Acid, Glutamine, Glycine, Histidine, Homocystine, Hydroxyproline, Isoleucine, Leucine, Lysine, Methionine, Ornithine, Phenylalanine, Phosphoethanolamine, Phosphoserine, Proline, Serine, Taurine, Threonine, Tryptophan, Tyrosine, Valine

Intended Use

Amino Acid analysis is necessary for the diagnosis of a variety of inborn errors of metabolism. These include, but are not limited to, phenylketonuria, tyrosinemia, citrullinemia, non-ketotic hyperglycinemia, maple syrup urine disease, and homocystinuria. The assay is also key for the continued monitoring of treatment plans for these disorders and useful for assessing nutritional status of patients. Our methodology is highly accurate at very low levels as well as at elevated levels.

Methodology

Chromatography/Mass Spectrometry

Laboratory Section

Special Test

Special Instructions/Patient Preparations

Collect plasma specimens after an overnight fast (or at least 4 hours after a meal). Non-fasting samples are acceptable for pediatric patients

Collection/Sample Container

2pcs Sodium heparin (green-top) tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

 

 

4mL Sodium Heparin Plasma

Alternative Specimen and Volume Requirement

Not Applicable

 

Specimen Stability

•   Room Temperature (15-25°C)

Unacceptable

•   Refrigerated Temperature (2-8°C)

 

7 days

•   Freezer Temperature (-20°C)

30 days

Transport Temperature

Transport specimen at 2°C - 8°C (with cold packs)

Rejection Criteria

Gross hemolysis

Running Day

Batch running

Cut Off Time

Monday, 12:00 PM

TAT/Releasing of Results

14 Working days (excluding saturday, sunday and holidays)

Reference Interval/Result Interpretation

Not Applicable

Limitations/Interferences

Not Applicable

Frequently Asked Questions (FAQs)

Not Applicable

Related Words/Test

Not Applicable

 

 

 

Test

Amiodarone (HPLC)

Other Test Request Name

  • Cordarone
  • Pacerone
  • Desethylamiodarone

Test Composition

Not Applicable

Intended Use

Amiodarone is an antiarrythmic drug.

Therapeutic drug monitoring is useful to monitor compliance and avoid toxicity.

Methodology

High Performance Liquid Chromatography (HPLC) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)

Laboratory Section

Special Test

Special Instructions/Patient Preparations

No patient preparation necessary.

Collection/Sample Container

Red tube (DO NOT USE GOLD TUBE or any other type of tube with gel separator)

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

 

5 mL Serum

Alternative Specimen and Volume Requirement

Not Applicable

Specimen Stability

•   Room Temperature (15-25°C)

24 Hours

•   Refrigerated Temperature (2-8°C)

 

 

3 Days

•   Freezer Temperature (-20°C)

28 Days

Transport Temperature

 

Transport specimen at 2 – 8 °C (with cold packs)

Rejection Criteria

  • Hemolyzed specimen
  • Quantity Not sufficient
  • Markedly lipemic sample
  • Improperly labeled specimen
  • Gel Barrier / Serum Separator Tube (SST)

Running Day

Batch Running

Cut Off Time

Monday, 12:00 PM

TAT/Releasing of Results

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Reference Interval/Result Interpretation

Available upon request

Limitations/Interferences

None specified.

Frequently Asked Questions (FAQs)

 

 

 

Not applicable

Related Words/Test

Treat life-threatening arrhythmias

 

 

 

 

 

 

 

Test

Ammonia (NH3)

Other Test Request Name

NH3

Test Composition

Not applicable

Intended Use

• Used to detect an elevated level in the blood that can be caused by severe liver disease, kidney failure, Reye syndrome or a rare genetic disorder of the urea cycle
• May be used to help investigate the cause of an individual's changes in behavior and consciousness

Methodology

Glutamate Dehydrogenase

Laboratory Section

Chemistry

Special Instructions/Patient Preparations

Patient Preparation:
8-12 hours fasting.
Note:
• Prolonged fasting is highly discouraged since various metabolic changes associated with starvation may begin to develop. Water intake is acceptable.
• Refrain from smoking for 8-12 hours prior to sample collection
• Avoid strenuous exercise for several hours prior to sampling
Sample collection:
• Notify laboratory personnel that a blood sample for ammonia level will be arriving.
• Leaving a tourniquet in place no more than 15 seconds, draw blood specimen. If syringe is used, uncap tube and transfer blood without using the needle. Mix blood.
• Keep sample tightly stoppered to avoid evaporation and contamination
• Separate plasma from red cells within 15 minutes of collection.
• Keep sample on ice until analysis.
• Send sample to HPD Main Laboratory immediately.

Collection/Sample Container

EDTA or Violet top

 

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

1-3 mL Plasma (EDTA)

Alternative Specimen and Volume Requirement

1- 3 mL Plasma (Li?heparin, Na- heparin)
NOTE: Do not use Ammonium Heparin

Specimen Stability

•   Room Temperature (15-25°C)

Unacceptable

•   Refrigerated Temperature (2-8°C)

2 Hours

•   Freezer Temperature (-20°C)

 

 

3 Weeks

Transport Temperature

 

  • Transport specimen at 2°C – 8 °C (with cold packs) if sample transport can be done in 2 hours.
  • Transport frozen if sample will be transported for more than 2 hours

Rejection Criteria

  • Improper collection tube used
  • Specimen stored/transported outside the temperature range
  • Quantity not sufficient
  • Specimens that failed the serum index criteria
  • Improperly labeled specimen

 

 

Running Day

Daily

Cut Off Time

Monday to Saturday:  6:00 PM

Sunday:4:00PM

TAT/Releasing of Results

ROUTINE (on running days)
• 4 hours after receipt of specimen/ arrival of messenger

STAT (on running days only)
• 2½ hours from extraction/messenger arrival

 

 

Reference Interval/Result Interpretation

18.00-72.00 umol/L  (31.00-123.00 ug/dL)

Limitations/Interferences

 

  • Sulfasalazine and its metabolite Sulfapyridine at therapeutic concentrations may lead to falsely low results.
  • Temozolomide and its metabolite MTIC may lead to falsely elevated results and its metabolite AIC may lead to falsely low results.

Frequently Asked Questions (FAQs)

Q: Can serum be used to test for Ammonia?
A: No, serum should not be used for ammonia measurements because ammonia is produced during the clotting process.

Related Words/Test

Liver Panel, ALT, AST, ALP, Glucose Tests, Electrolytes, Renal Panel

 

 

 

Test

Amphetamine

Other Test Request Name

• Eye opener
• Lid poppers
• Pep pills
• Uppers
• Hearts
• Wonder drugs

Test Composition

Not applicable

Intended Use

Used as a screening test for qualitative detection of amphetamine in urine.

Methodology

Lateral Flow Immunochromatography (Competitive Binding)

Laboratory Section

Drug Test

Special Instructions/Patient Preparations

No patient preparation necessary

Collection/Sample Container

60-mL clean, screw cap, polyethylene container

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

60 mL urine

Alternative Specimen and Volume Requirement

Not applicable

Specimen Stability

•   Room Temperature (15-25°C)

Not specified

•   Refrigerated Temperature (2-8°C)

48 Hours

•   Freezer Temperature (-20°C)

Not specified

Transport Temperature

Not applicable

Rejection Criteria

• Incompatibility of the ID number on the specimen received by the laboratory with the number on the CCF.
• Absence of ID number on the specimen
• No printed Authorized Specimen Collector’s name and signature on the CCF.
• Broken or tampered seal on the specimen container
• Insufficient quantity of specimen, below 60 mL for single collection; below 30 mL for spilt collection

Running Day

Daily

Cut Off Time

Monday to Saturday
• 6:00 PM

Sunday
• 3:00 PM

TAT/Releasing of Results

ROUTINE
• 3 hours after receipt of specimen/ arrival of messenger
STAT
• After 1½ hours from receipt of specimen/ arrival of messenger

Reference Interval/Result Interpretation

Not applicable

Limitations/Interferences

• Other drugs with the same structure with the abused drugs
• Cross-reactant chemicals
• Bleach or alum

Frequently Asked Questions (FAQs)

Not applicable

Related Words/Test

Not applicable

 

Test

Amylase (ENZYMATIC)

Other Test Request Name

• Amy
• Amyl

Test Composition

Not applicable

Intended Use

• Used to help diagnose and monitor acute pancreatitis.
• May also be used to diagnose and monitor chronic pancreatitis and other disorders that may involve the pancreas.

Methodology

Enzymatic (Two point rate)

Laboratory Section

Chemistry

Special Instructions/Patient Preparations

• No patient preparation necessary.

Collection/Sample Container

Red or Gold tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

1-3 mL Serum

Alternative Specimen and Volume Requirement

1-3 mL Plasma (Heparin)

Specimen Stability

•   Room Temperature (15-25°C)

7 Days

•   Refrigerated Temperature (2-8°C)

7 Days

•   Freezer Temperature (-20°C)

1 Year

Transport Temperature

Transport specimen at 2 – 8 °C (with cold packs)

Rejection Criteria

  1. Failed serum index samples
  2. Specimen stored/transported outside the temperature range
  3. Quantity not sufficient
  4. Improperly labeled specimen
  5. Improper collection tube used
  6. EDTA plasma

 

 

 

Running Day

Daily

Cut Off Time

Monday to Saturday:6:00 PM

Sunday:4:00PM

TAT/Releasing of Results

ROUTINE
• 4 hours after receipt of specimen/ arrival of messenger
STAT
• After 2½ HOURS from extraction/messenger arrival

Reference Interval/Result Interpretation

0 day -28 days : 5.00~65.00 U/L
29 days - 70 Y/O : 25.00~125.00 U/L
70Y and 1 Day – 999 Y/O : 20.00~160.00 U/L

Limitations/Interferences

None identified.

Frequently Asked Questions (FAQs)

Not applicable

Related Words/Test

Lipase, Trypsin, Trypsinogen

 

 

 

 

 

 

 

 

 

 

 

Test

Amyloid (PTAU) Test

Other Test Request Name

  • Phosphorylated tau protein
  • ABETA 1-42 protein
  • Alzheimer
  • Amyloid beta-protein
  • TAU - PTAU - Amyloid proteins - CSF

Test Composition

Not Applicable

Intended Use

To help distinguish between Alzheimer disease and other forms of dementia.

Methodology

Enzyme-immunoassay

Laboratory Section

Special Test

Special Instructions/Patient Preparations

FOR BRANCHES:
  • No patient preparation necessary.
  • Ask for Specific Clinical Information Form (R34-INTGB) at Special Test Section atleast one day prior submission of sample.
  • Request Container (Polyprophylene Sample Tube) to Special test section
  • Inform laboratory (Special test section) and Logistics (for Special Trip) 1 day before sample collection.
  • Specimen should be at Special Test Section within 2 Hours from the time of collection

FOR SPECIAL TEST SECTION:

  • Centrifuge the sample for 10 minutes at 2000g at 12 /− 5 °C
  • Label the 6 microtubes with patient's complete name and date of birth
  • Aliquot the supernatant into 6 fractions of 500 μl into the micro tubes supplied by Referring Laboratory
  • Freeze the 6 aliquots at -20°C
  • Request addional DRY ICE for shipment abroad atleast 10kilos on shipout day.

 

 

 

 Collection/Sample Container

Polyprophylene Sample Tube (Provided by Special Test Section)

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

5 mL Cerebrospinal Fluid (CSF)

Alternative Specimen and Volume Requirement

Not Applicable

Specimen Stability

•   Room Temperature (15-25°C)

Not Applicable

•   Refrigerated Temperature (2-8°C)

2 Hours

•   Freezer Temperature (-20°C)

28 Days

Transport Temperature

Transport specimen at 2°C - 8°C (with cold packs)

Rejection Criteria

  • Not properly labeled tube
  • Incomplete details of the patient
  • Hemolyzed sample
  • Lipemic sample
  • Quantity not sufficient sample
  • Incomplete documents needed
  • Beyond sample stability
  • Wrong sample container

Running Day

Batch Running

Cut Off Time

Friday, 12:00 PM

TAT/Releasing of Results

3 months after cut-off (excluding saturdays, Sundays and Holidays)

Reference Interval/Result Interpretation

Available Upon Request

 

 

 

 

 

 

 

 

 

Limitations/Interferences

None Specified.

Frequently Asked Questions (FAQs)

Q: What is being tested?

A:Two separate laboratory tests can measure amyloid beta 42 (beta amyloid) and tau protein in cerebrospinal fluid (CSF). These tests are often done at the same time to help evaluate an individual for Alzheimer disease (AD).

  • Amyloid beta 42 is a peptide (protein fragment). Increased production of amyloid beta 42 in the brain can lead to the formation of amyloid plaques.
  • Tau is a structural protein in the brain. Tau protein containing many phosphorus groups (P-tau) can produce neurofibrillary tangles, which are twisted protein fragments that develop in nerve cells and disrupt the cells' ability to transport signals.

  Neurofibrillary tangles and amyloid plaques are considered to be the main diagnostic features of Alzheimer disease.

The measurements of tau and beta amyloid in CSF are being evaluated for potential roles in the diagnosis and monitoring of AD. It has been shown that a decrease in beta amyloid with elevated tau or P-tau levels may predict the onset of AD.

Q: When to get tested?

A:These tests may be ordered along with cognitive and brain-imaging tests in people who demonstrate some form of dementia. These tests are not routine laboratory tests and are typically available only in research settings or memory clinics.

Q: How is the test used?

A: Lab tests for tau protein and beta amyloid may be used as supplemental tests to help evaluate a person suspected of having Alzheimer disease (AD) and to distinguish between AD and other forms of dementia. These tests are not widely used or routinely ordered. Use of these tests is limited to people suspected of having dementia, and testing is typically performed after other causes of a person's symptoms have been ruled out.

Q: When it is ordered?

A: Tau protein and beta amyloid tests are primarily performed in research settings and in some memory clinics. The tests may be done along with cognitive tests and brain scans when an individual has signs and symptoms of Alzheimer disease, such as:

  • Loss of memory that affects daily life—forgetting information that was recently learned. This can occur with normal aging, but the information is usually remembered later. This includes forgetting important dates or events, having to rely on memory aids, and asking for the same information again and again.
  • Difficulty planning or problem solving, such as keeping track of bills and payments
  • Problems completing usual tasks, such as forgetting how to get to a familiar location
  • Confusion about place or time—losing track of time, forgetting where you are or how you got there
  • Increasing difficulty reading or judging distances
  • Problems speaking or writing—forgetting words, repeating the same thing, struggling with vocabulary
  • Losing things more frequently and not being able to logically retrace steps to find them
  • Impaired judgment, such as giving away unusually large amounts of money
  • Increasing withdrawal from activities, including social, work or family events
  • Changes in mood and personality, such as increasing anxiety, fear, suspicion and depression

  Some healthcare practitioners may order these tests for other reasons; however, information on how to interpret the results outside of the settings described above is limited.

Q:  What tests are usually done to evaluate a person for Alzheimer disease?

A:If someone has symptoms of dementia, a healthcare practitioner will do a thorough work-up to try to determine the cause. This work-up may include a variety of cognitive tests (such as a Minimal Mental State Exam) to assess memory and possibly PET scanning tests of the brain to look for abnormalities. Read the article on Alzheimer Disease for additional details.

 

 

 

Related Words/Test

APOE Genotyping, Alzheimer Disease,PSEN1

 

 

 

 

Test

Anti HBc Total (CMIA)

Other Test Request Name

  • Hepatitis B core Total Antibody
  • Anti HBc IgG - Anti HBc Total (not specific for IgG) is the replacement test for Anti HBc IgG.

Test Composition

Not applicable

Intended Use

Anti-HBc determinations can be used as an indicator of current or past HBV infection.

Methodology

Chemiluminescent Microparticle Immunoassay (CMIA)

Laboratory Section

Immunology

Special Instructions/Patient Preparations

No patient preparation necessary.

Collection/Sample Container

Red or Gold tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

1-3 mL Serum

Alternative Specimen and Volume Requirement

1-3 mL Plasma (Li-Heparin (PST), Na-Heparin, K-EDTA, Na-citrate, ACD, CPDA-1, CPD, and Potassium oxalate)

 

 

Specimen Stability

•   Room Temperature (15-25°C)

Not specified

 

•   Refrigerated Temperature (2-8°C)

14 Days

•   Freezer Temperature (-20°C)

6 Freeze-Thaw cycles

 

Transport Temperature

Transport specimen at 2°C – 8 °C (with cold packs)

Rejection Criteria

• Hemolyzed specimen
• Markedly lipemic specimen
• Specimen stored/transported outside the temperature range
• Quantity not sufficient
• Improperly labeled specimens

Running Day

Tuesday, Wednesday, Thursday, Friday, Saturday

Cut Off Time

Monday to Saturday:6:00 PM

TAT/Releasing of Results

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

 Reference Interval/Result Interpretation

• NON-REACTIVE: C.O.V. 0.000~0.900
• GRAYZONE: C.O.V. 0.901~1.100
• REACTIVE: C.O.V. GREATER THAN (>) 1.100

Limitations/Interferences

• Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis of therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with this assay.
• Hemophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed. Additional information may be required for diagnosis.

Frequently Asked Questions (FAQs)

Not applicable

 

 

 

Related Words/Test

Hepatitis B, HBV, HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus

 

 

 

 

 

 

Test

Anti HBe (CMIA)

Other Test Request Name

Hepatitis B envelope Antibody

Test Composition

Not applicable

Intended Use

Used to monitor acute infections in those who have recovered from acute hepatitis B infection

Methodology

Chemiluminescent Microparticle Immunoassay (CMIA)

Laboratory Section

Immunology

Special Instructions/Patient Preparations

No patient preparation necessary.

Collection/Sample Container

Red or Gold tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

1-3 mL Serum

Alternative Specimen and Volume Requirement

1-3 mL Plasma (K-EDTA, Na-citrate, ACD-B, CPDA-1, CPD, and Na-Heparin, Potassium oxalate)

 

 

 

Specimen Stability

•   Room Temperature (15-25°C)

Not specified

•   Refrigerated Temperature (2-8°C)

7 Days

•   Freezer Temperature (-20°C)

6 Freeze-Thaw cycles

Transport Temperature

Transport specimen at 2°C – 8 °C (with cold packs)

 

Rejection Criteria

• Hemolyzed specimen
• Markedly lipemic specimen
• Specimen stored/transported outside the temperature range
• Quantity not sufficient
• Improperly labeled specimens

Running Day

Tuesday, Wednesday, Thursday, Friday, Saturday

Cut Off Time

Monday to Saturday: 6:00 PM

TAT/Releasing of Results

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

Reference Interval/Result Interpretation

 

 

 

NOTE: Anti-HBe count below the cut-off value is considered REACTIVE.

• NON-REACTIVE: C.O.V. GREATER THAN (>) 1.100
• GRAYZONE: C.O.V. 0.900~1.100
• REACTIVE: C.O.V. LESS THAN (<) 0.900

Limitations/Interferences

•Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis of therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with this assay.
•Hemophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed. Additional information may be required for diagnosis.

Frequently Asked Questions (FAQs)

Not applicable

Related Words/Test

Hepatitis B, HBV, HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus

 

 

 

Test

Anti HBs (CMIA)

Other Test Request Name

Hepatitis B surface Antibody

Test Composition

Not applicable

Intended Use

• Anti-HBs assays are often used to monitor the success of Hepatitis B vaccination.
• Assays for Anti-HBs are also used to monitor the convalescence and recovery of Hepatitis B infected individuals.

Methodology

Chemiluminescent Microparticle Immunoassay (CMIA)

Laboratory Section

Immunology

Special Instructions/Patient Preparations

No patient preparation necessary.

Collection/Sample Container

Red or Gold tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

1-3 mL Serum

Alternative Specimen and Volume Requirement

1-3 mL Plasma (K-EDTA, Na-citrate, ACD, CPDA-1, and Na-Heparin)

Specimen Stability

•   Room Temperature (15-25°C)

Not specified

•   Refrigerated Temperature (2-8°C)

14 Days

•   Freezer Temperature (-20°C)

4 Freeze-Thaw cycles

Transport Temperature

Transport specimen at 2°C – 8 °C (with cold packs)

Rejection Criteria

• Hemolyzed specimen
• Markedly lipemic specimen
• Specimen stored/transported outside the temperature range
• Quantity not sufficient
• Improperly labeled specimens

 

 

 

 

 

 

 

 

Running Day

Monday, Tuesday, Wednesday, Thursday, Friday, Saturday

Cut Off Time

Monday to Saturday:10:00 PM

Sunday:6:00PM

TAT/Releasing of Results

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

Reference Interval/Result Interpretation

• NON-REACTIVE: C.O.V   0.000~9.000 mIU/mL
• GRAYZONE: C.O.V.  9.010~11.000 mIU/mL
• REACTIVE: GREATER THAN (>) 11.000 mIU/mL

Limitations/Interferences

Not applicable

Frequently Asked Questions (FAQs)

Not applicable

 

 

Related Words/Test

Hepatitis B, HBV, HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface Antigen; HBeAg; Hepatitis B e Antigen; anti-HBc; Hepatitis B Core Antibody; anti-HBc, IgM; anti-HBe; Hepatitis B e Antibody; HBV DNA, Hepatitis B Virus

 

 

 

 

Test

Anti HCV (CMIA)

Other Test Request Name

Hepatitis C Antibody

Test Composition

Not applicable

Intended Use

Used as an aid in the diagnosis of Hepatitis C infection and as a screening test to prevent transmission of Hepatitis C virus (HCV) to recipients of blood, blood components, cells, tissue and organs.

Methodology

Chemiluminescent Microparticle Immunoassay (CMIA)

Laboratory Section

Immunology

Special Instructions/Patient Preparations

• No patient preparation necessary.

Collection/Sample Container

Red or Gold tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

1-3 mL Serum

Alternative Specimen and Volume Requirement

1-3 mL Plasma (K-EDTA, Na- or Li-heparin, CPD, CPDA-1, Na-citrate, ACD, CP2D, Potassium Oxalate)

 

 

 

Specimen Stability

•   Room Temperature (15-25°C)

Not specified

•   Refrigerated Temperature (2-8°C)

7 Days

•   Freezer Temperature (-20°C)

6 Freeze-Thaw cycles

Transport Temperature

Transport specimen at 2°C – 8 °C (with cold packs)

Rejection Criteria

• Hemolyzed specimen
• Markedly lipemic specimen
• Specimen stored/transported outside the temperature range
• Quantity not sufficient
• Improperly labeled specimens

 

 

 

 

Running Day

Monday, Tuesday, Wednesday, Thursday, Friday, Saturday

Cut Off Time

Monday to Saturday:10:00 PM

Sunday:6:00PM

TAT/Releasing of Results

ROUTINE (on running days)
• 6 hours after receipt of specimen/ arrival of messenger
STAT (on running days only)
• 2½ hours from extraction/messenger arrival

 

 

Reference Interval/Result Interpretation

• NON-REACTIVE: C.O.V. 0.000~0.800
• GRAYZONE: C.O.V. 0.810~1.200
• REACTIVE, LOW TITER: C.O.V. 1.210~5.000
• REACTIVE: C.O.V. GREATER THAN (>) 5.000

Limitations/Interferences

False positive results can be expected with any test kit. The proportion of these falsely reactive specimens is dependent upon the specificity of the test kit, specimen integrity, and on the prevalence of HCV antibodies in the population being screened.

Frequently Asked Questions (FAQs)

Not applicable

Related Words/Test

Hepatitis C, HCV, Hepatitis C Antibody; Anti-HCV; HCV-PCR; HCV-RNA; Hepatitis C Viral LoadViral Hepatitis C Antibody Screen; Viral Hepatitis C RNA by PCR; Hepatitis C Virus Genotype

 

 

 

 

 

 

Test

Anti Histones (EIA)

Other Test Request Name

  • Histone Autoantibodies
  • Histones - Anti-Antibodies
  • Antihistone Antibody
  • Histone Antibody

 Test Composition

Not Applicable

Intended Use

A marker for lupus. In the absence of anti-double stranded DNA antibodies, the presence of antihistone antibodies is suggestive of drug-induced lupus.

Methodology

Enzyme Immunoassay (EIA)

Laboratory Section

Special Test

Special Instructions/Patient Preparations

No patient preparation necessary.

 

Collection/Sample Container

Red or Gold tube

Specimen and Volume Requirement
Note:Follow tube manufacturer recommendation.

3 mL Serum

Alternative Specimen and Volume Requirement

Not Applicable

Specimen Stability

•   Room Temperature (15-25°C)

24 Hours

•   Refrigerated Temperature (2-8°C)

7 Days

•   Freezer Temperature (-20°C)

28 Days

Transport Temperature

Transport specimen at 2 – 8 °C (with cold packs)

Rejection Criteria

  • Hemolyzed specimen
  • Quantity Not sufficient
  • Improperly labeled specimen
  • Markedly lipemic sample

Running Day

Batch Running

Cut Off Time

Friday, 4:00 PM

TAT/Releasing of Results

2 weeks after cut-off (excluding Saturdays, Sundays and Holidays)

Reference Interval/Result Interpretation

Available upon request

 

 

 

 

 

 

Limitations/Interferences

None specified.

Frequently Asked Questions (FAQs)

Q: Why get tested?

A:To help in the diagnosis and monitoring of drug-induced lupus

Q: When to get tested?

A:When you have symptoms associated with lupus that may be due to a drug that you are taking

Q: What are the common examples of drugs that has been associated of drug-induced lupus in some people?

A:Many drugs have been associated with drug-induced lupus in some people. Some of the more common examples include:

  • Hydralazine
  • Isoniazid
  • Minocycline
  • Penicillamine
  • Procainamide
  • Quinidine

Q: What are the other types of medication associated with drug induced lupus?

A: Other types of medications associated with drug-induced lupus include:

  • Antibiotics
  • Anti-seizure medications
  • Anti-tumor necrosis factor (anti-TNF) agents
  • Interferon-alpha
  • Blood pressure medications
  • Methyldopa
  • Thyroid medications

Q: When is it ordered?

A:A histone antibody test is ordered when a person has been taking a drug for several weeks to a couple of years and develops signs and symptoms that could be due to drug-induced lupus. This is especially true when the person affected did not have a prior personal or family history of an autoimmune disorder. Symptoms may include:

  • Arthritis-like pain in one or more joints (but no or little joint inflammation)
  • Fatigue
  • Fever
  • Muscle pain (myalgia)
  • Red rash that frequently resembles a butterfly across the nose and cheek areas (malar rash)
  • Sensitivity to sunlight
  • Weight loss
     

Symptoms and complications involving the central nervouse system (CNS) and kidneys occur with SLE but are much rarer with drug-induced lupus.

The histone antibody test may be repeated at intervals after the drug has been discontinued to monitor for decreases in histone antibody levels.

Q: What can I do to change my histone antibody level?

A:Talk to your healthcare practitioner about discontinuing the potentially offending drug. When this is done, the histone antibody level should drop over time. Histone antibody levels do not respond to lifestyle changes.

 

 

Related Words/Test

SLE / Lupus, Antinuclear Antibody (ANA), Autoantibodies, Anti-dsDNA, Extractable Nuclear Antigen Antibodies (ENA) Panel